AAV-hAADC gene therapy - Agilis/National Taiwan University

Drug Profile

AAV-hAADC gene therapy - Agilis/National Taiwan University

Alternative Names: AADC deficiency gene therapy programme - Agilis; AAV2-hAADC - Agilis/National Taiwan University; AGIL-AADC

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Taiwan University
  • Developer Agilis Biotherapeutics; National Taiwan University
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn error metabolic disorders

Most Recent Events

  • 03 Oct 2017 Agilis Biotherapeutics announces intention to submit regulatory applications in Europe and Japan
  • 03 Oct 2017 Pooled efficacy data from clinical trials in Inborn error metabolic disorders released by Agilis Biotherapeutics
  • 06 Sep 2017 Agilis Biotherapeutics announces intention to submit BLA to US FDA for Inborn error metabolic disorders in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top